Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Canaccord Genuity Wealth Limited - Form 8.3 - [ALLIANCE PHARMA PLC - 08 05 2025] - (CGWL)
Form 8.3 - [ALLIANCE PHARMA PLC - 08 05 2025] - (CGWL)
GlobeNewswire

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) (a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED…

globenewswire.com - Zealand Pharma - Zealand Pharma announces closing of collaboration and license agreement with Roche
Zealand Pharma announces closing of collaboration and license agreement with Roche
GlobeNewswire

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq:…

afaqs.com - afaqs! news bureau - Sun Pharma launches corporate brand campaign in India
Sun Pharma launches corporate brand campaign in India
afaqs!

Sun Pharmaceutical Industries (Sun Pharma) has launched a corporate brand campaign titled ‘Touching 1,000 Lives Every Minute'. The campaign highlights the company's role in supporting patients, caregivers, doctors, pharmacists, and…

thedailystar.net - Beximco Pharma signs MoU with NSU for research collaboration
Beximco Pharma signs MoU with NSU for research collaboration
The Daily Star

Beximco Pharmaceuticals and the Department of Pharmaceutical Sciences of North South University (NSU) have entered a Memorandum of Understanding (MoU) aimed at fostering research, innovation, and career development in the pharmaceutical sector. The…

bloomberg.com - Rachel Cohrs Zhang - GOP Eyes Pharma Tax Hike, Nixing Drug Price Deal for Trump Bill
GOP Eyes Pharma Tax Hike, Nixing Drug Price Deal for Trump Bill
Bloomberg

House Republicans are considering nixing a Medicaid drug pricing plan floated by President Donald Trump and fiercely opposed by the pharmaceutical industry as the party pushes to strike a massive tax and spending deal in the coming days. But…

irishcentral.com - Brian Mahon - Pharma exports from Ireland to the US doubled 'to avoid Trump tax bills'
Pharma exports from Ireland to the US doubled 'to avoid Trump tax bills'
IrishCentral

Pharma exports from Ireland to the US multiplied in February and March as firms rushed to avoid Donald Trump's huge tariffs. Around half a year's supply of medicines, worth $42 billion, were shipped to the US from Ireland and stockpiled in advance…

chron.com - Andrea Guzmán - H-E-B joins other retailers in lawsuit against pharma companies
H-E-B joins other retailers in lawsuit against pharma companies
Chron

Texas grocer H-E-B, along with Kroger, Albertsons and Walgreen Co., is accusing pharmaceutical companies of hurting competition. A recently filed lawsuit alleges Japanese drug maker Takeda Pharmaceutical and Taiwan-based TWi Pharmaceuticals made a…

business-standard.com - Capital Market - Sensex slides 579 pts; pharma shares decline for 4th day
Sensex slides 579 pts; pharma shares decline for 4th day
Business Standard

The key equity indices traded with major losses in mid-morning trade as escalating tensions between India and Pakistanintensified by the ongoing Operation Sindoorkept investors on edge. Market sentiment is likely to remain volatile in the near…

seekingalpha.com - SA Transcript Insights Editor - Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan (NASDAQ:RPRX)
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan (NASDAQ:RPRX)
Seeking Alpha

Earnings Call Insights: Royalty Pharma (RPRX) Q1 2025 CEO Pablo Legorreta emphasized a strong start to 2025, highlighting 12% growth in Royalty Receipts and a 17% increase in Portfolio Receipts, driven by the company's diversified portfolio and…

axios.com - Dan Primack - Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Axios

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new challenge in the form of Vinay Prasad, who this week was named to lead the FDA's Center for Biologics Evaluation and…

seekingalpha.com - Edmund Ingham - Organon: Management Slashes Dividend - This Feels Disastrous (NYSE:OGN)
Organon: Management Slashes Dividend - This Feels Disastrous (NYSE:OGN)
Seeking Alpha

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its…

seekingalpha.com - Edmund Ingham - Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS)
Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS)
Seeking Alpha

Viatris Inc.'s Q1 2025 earnings show declining revenues and profits, yet the stock rose nearly 10% due to stable full-year guidance and positive pipeline updates. The company's significant debt reduction from $22.4bn to $14.3bn came at the cost of…

townhall.com - Ryan Costello - Delivering Lower Rx Prices for the American People
Delivering Lower Rx Prices for the American People
Townhall

“For generations, the American people have been abused by Big Pharma.” President Trump said those words during his first administration, and it still reins true to this day as the White House recently elevated the importance of…

dailymail.co.uk - David Wilcock, Deputy Political Editor For Mailonline - Ministers deny handing Trump a China 'veto' in new US trade deal
Ministers deny handing Trump a China 'veto' in new US trade deal
Mail Online

Donald Trump will not be able to 'veto' Chinese investment in the UK under the terms of a new US trade deal, a senior minister said today. Darren Jones said reports that the White House would be able to block sources of foreign cash were…

cnbc.com - Matthew J. Belvedere - Trump's trade saga is further proof that trying to time the stock market is a fool's errand
Trump's trade saga is further proof that trying to time the stock market is a fool's errand
CNBC

The market has almost come full circle. Following President Donald Trump 's announcement of a U.K. trade deal, the S & P 500 on Thursday rose as much as 1.6% to 5,720 — its highest intraday level since late March, when the index was still on…

Receive a Daily briefing on Pharma Industry News

Get Started